Latest news articles

Added 4 days ago Drug news

CHMP recommends Zeposia to treat adult patients with relapsing remitting multiple sclerosis.- BMS

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has...

Added 5 days ago Drug news

FDA approves Zeposia to treat relapsing forms of multiple sclerosis ,including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.-BMS

Bristol-Myers Squibb Company announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms...

Added 18 days ago Drug news

Mayzent is approved in Canada to treat secondary progressive multiple sclerosis.- Novartis

Novartis Pharmaceuticals Canada Inc. announces that Health Canada has approved Mayzent (siponimod) for the treatment of adults with secondary progressive...

Search all news articles for Multiple sclerosis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Guidelines

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

Added 3 months ago

Multiple sclerosis in adults: management

This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for adults with multiple sclerosis by promoting symptom management...

Added 5 years ago

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use.

Added 4 years ago

Search all guidelines for Multiple sclerosis
 

Journal articles

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.

Background: In the past, multiple sclerosis (MS) medications have been primarily designed to modulate T cell properties. Based on the emerging concept that B cells are equally important for the propagation of MS, we compared...

Added 4 months ago

Interleukin 18 Polymorphisms and its serum level in Patients with Multiple Sclerosis.

Propose: To determine the serum level of interleukin-18 (IL-18) as well as gene polymorphisms of IL-18 (rs1946518, rs360719, and rs187238).

Added 4 months ago

Long-range connections are more severely damaged and relevant for cognition in multiple sclerosis.

An efficient network such as the human brain features a combination of global integration of information, driven by long-range connections, and local processing involving short-range connections.

Added 4 months ago

Search all journal articles for Multiple sclerosis
 

Clinical trials

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years.

Added 4 months ago

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo...

Added 5 months ago

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

This 2-year study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages >/= 10 to < 18 years with relapsing-remitting multiple sclerosis (RRMS).

Added 5 months ago

Search all clinical trials for Multiple sclerosis
 

CME

Multiple sclerosis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
2
Registration required
0
Subscription fee
0
Search all CME for Multiple sclerosis